Amount of suitable patients: CDEC mentioned the uncertainty in the quantity of clients with reasonably serious to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're classified as getting moderate or average sickness can have a critical bleeding p